CSIMarket
 
Elanco Animal Health Incorporated  (NYSE: ELAN)
 
Price: $22.7050 $-0.16 -0.678%
Day's High: $23.31999969482422 Week Perf: -7.33 %
Day's Low: $ 22.66 30 Day Perf: 2.6 %
Volume (M): 571,115 52 Wk High: $ 28.00
Volume (M$): $ 0 52 Wk Avg: $23.19
Open: $23.20 52 Wk Low: $18.22



 Market Capitalization (Millions $) 11,486
 Shares Outstanding (Millions) 506
 Employees 9,900
 Revenues (TTM) (Millions $) 5,020
 Net Income (TTM) (Millions $) -199
 Cash Flow (TTM) (Millions $) -111
 Capital Exp. (TTM) (Millions $) 238

Business Description


Elanco Animal Health Inc. is a global animal health company headquartered in Greenfield, Indiana, in the United States. The company develops, produces, and markets innovative products for animal health, including veterinary drugs, vaccines, feed additives, and other products for animal health and productivity. Elanco provides animal health products to farmers, pet owners, and veterinarians worldwide.

Elanco was founded in 1954 as a division of Eli Lilly and Company, a pharmaceutical company. In 2018, Elanco was spun off from Eli Lilly and Company to become a standalone company. Elanco has more than 6,000 employees and operates in more than 90 countries worldwide.

Elanco offers a wide range of animal health products for various species, including cattle, swine, poultry, fish, pets, and other companion animals. The company's products are built on innovative technologies that help improve animal health, welfare, and productivity.

Elanco's product portfolio includes antibiotics, parasiticides, vaccines, anticoccidials, enzymes, and other feed additives. The company has a strong presence in global markets, particularly in North America, Europe, and Asia Pacific.

In addition to its commercial products, Elanco is committed to developing sustainable solutions to address the challenges facing the animal farming industry. The company invests in research and development of new products and solutions that promote animal welfare and sustainability.

Elanco has a strong commitment to corporate social responsibility and sustainability. The company focuses on improving animal welfare, protecting the environment, and engaging in social responsibility initiatives in the communities where it operates. Elanco is a member of the United Nations Global Compact, a voluntary initiative that promotes sustainable and socially responsible business practices.

Overall, Elanco has a strong reputation in the animal health industry as a leading provider of innovative and effective animal health products. The company's commitment to sustainability and corporate social responsibility has earned it recognition as a responsible and ethical corporate citizen.


   Company Address: 450 ELANCO CIRCLE INDIANAPOLIS 46221 IN
   Company Phone Number: 352-6261   Stock Exchange / Ticker: NYSE ELAN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MRK   -5.04%    
PAHC   -7.21%    
VTRS   -2.95%    
ZTS   -5.16%    
ICCC   -1.5%    
IDXX   -5.05%    
• View Complete Report
   



Announcement

Investors Alert Class Action Lawsuit Filed Against Elanco Animal Health Inc. Over Securities Issues

Published Thu, Nov 21 2024 6:18 PM UTC

On November 21, 2024, Levi & Korsinsky, LLP announced it has formally notified investors of a class action securities lawsuit targeting Elanco Animal Health Incorporated, a company listed on the New York Stock Exchange under the ticker symbol ELAN. This lawsuit concerns allegations that may have significant implications for Elanco’s investors.As a prominent entity in the a...

Announcement

Elanco Animal Health Faces Class Action Lawsuit Investors Seek Damages Amid Allegations of Misleading Securities Pr...

Published Thu, Oct 10 2024 4:18 PM UTC

In an alarming development in the realm of securities regulation, Gainey McKenna & Egleston announced the filing of a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) in the United States District Court for the District of Maryland. This legal action comes on behalf of individuals and entities who purchased or otherwise acquired Elanco securities ...

Announcement

Delays in Product Launches Raise Concerns for Elanco Animal Health (ELAN) as Investor Losses Mount

Published Fri, Jul 12 2024 4:04 PM UTC

Elanco Animal Health (ELAN) Faces Scrutiny Over Delayed Product LaunchesElanco Animal Health Incorporated (NYSE: ELAN) is currently under scrutiny for its delayed product launches, causing substantial losses for investors. Hagens Berman, a renowned law firm, is urging affected investors to submit their losses for further investigation.The delays in product launches have rais...

Personnel Announcements

Elanco Animal Health Appoints Shiv O'Neill as General Counsel and Corporate Secretary, Strengthening Global Operations

Published Mon, Mar 4 2024 1:33 PM UTC



Elanco Animal Health, a prominent global animal health company, has made a strategic move to enhance its leadership team. On March 4, 2024, Elanco announced the appointment of Shiv O Neill as the company s Executive Vice President, General Counsel, and Corporate Secretary. This decision aims to strengthen Elanco s global strategy and operations, signaling the compa...

Contract

Harnessing Innovation: Athian and Elanco Animal Health Accelerate Sustainable Food Production through Methane Reduction

Published Thu, Nov 2 2023 11:16 AM UTC



In a groundbreaking partnership, Athian, a leading technology company, and Elanco Animal Health have joined forces to tackle one of the biggest challenges in the agriculture industry - methane emissions from livestock. The collaboration aims to transform food production by reducing enteric methane emissions and improving feed utilization through the use of innovati...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.29
Price to Sales (Expected) -
Price to Book 1.74
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.29
Working Capital Ratio 2.05
Leverage Ratio (MRQ) 1.47
Total Debt to Equity 1.19
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.16

Per Share Current
Earnings (TTM) -0.41 $
Revenues (TTM) 9.92 $
Cash Flow (TTM) -
Cash 1.05 $
Book Value 13.02 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 507,071
Net Income per Employee (TTM) -20,101
Receivable Turnover Ratio (TTM) 5.11
Inventory Turnover Ratio (TTM) 1.29
Asset Turnover Ratio (TTM) 0.37

Profitability Ratios Current
Gross Margin (MRQ) 58.33 %
Operating Margin (MRQ) 0 %
Net Margin (MRQ) 3.95 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Elanco Animal Health Incorporated's Segments
Pet Health    104.39 % of total Revenue
Cattle    45.98 % of total Revenue
Poultry    33.11 % of total Revenue
Swine    14.11 % of total Revenue
Farm Animal    93.2 % of total Revenue
Contract Manufacturing    2.63 % of total Revenue
United States    92.69 % of total Revenue
Non-US    107.53 % of total Revenue
Reportable    200.22 % of total Revenue

  Elanco Animal Health Incorporated Outlook

On November 7 2023 the Elanco Animal Health Incorporated provided following guidance

Elanco Animal Health Inc., a leading global company in the animal health industry, has released its financial results for the third quarter of 2023. The company experienced remarkable growth in both the pet health and farm animal sectors, reflected in its revenue, adjusted EBITDA, and adjusted EPS.

Elanco achieved significant growth in constant currency revenue, which expanded by 5 percent during the third quarter. This growth was primarily attributed to the increasing impact of innovative solutions and the stabilization of its core veterinary product offerings.

The company's commitment to advancing animal health and well-being has propelled its performance in both the pet health and farm anima...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.